-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EIxGQ6yEkudFhYT45tslKguno7QeeqXI/deVWVknNkzsOixG19XkgcKoD1Kwlzwn
 J7JbEJguHB3FMtY1qockDA==

<SEC-DOCUMENT>0001193125-07-135283.txt : 20070614
<SEC-HEADER>0001193125-07-135283.hdr.sgml : 20070614
<ACCEPTANCE-DATETIME>20070614082439
ACCESSION NUMBER:		0001193125-07-135283
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20070614
DATE AS OF CHANGE:		20070614
EFFECTIVENESS DATE:		20070614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		07918774

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>(RULE 14A-101)
</B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant: <FONT FACE="WINGDINGS">&#120;</FONT>
&nbsp;&nbsp;Filed by a Party other than the Registrant: </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CRYO-CELL INTERNATIONAL, INC. </B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"
ALIGN="left"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate
box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the form or schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, schedule or registration statement no.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g73952img01.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CRYO-CELL URGES SHAREHOLDERS TO VOTE THE WHITE PROXY CARD </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>Company&#146;s Maternal Placental Stem Cell Technology Believed to Be </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>&#147;One of the Most Seminal Assets in the Stem Cell Industry Today&#148; </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"><B>Oldsmar, Fla. &#150; June </B><B>14</B><B>, 2007 &#150; Cryo-Cell International Inc. (OTC Bulletin Board:
CCEL),</B> recently sent a letter to Cryo-Cell shareholders in conjunction with its Annual Shareholder Meeting to be held in Oldsmar, Florida on July 16</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2" COLOR="#000000">. The Company urged its shareholders to consider the Board&#146;s accomplishments and objectives described below. The Company stressed the importance of this vote and asked shareholders to vote their
shares on the <B>WHITE </B>proxy card that they will receive by mail. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Cryo-Cell Board of Directors has a proven track record of performance and a
solid strategic plan to achieve global leadership in stem cell innovation. In fiscal year 2003, which began before the current Board and management was in place; the Company had $7.55 million in revenue and $7.5 million in net losses. Approximately
a year and a half after current management was in place, revenue for fiscal year 2005 almost doubled to $14.5 million and the Company registered $1 million in net income. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">The Company delivered nine consecutive quarters of profitability from the first quarter of 2004 through the first quarter of 2006. Consolidated revenues in fiscal year 2006 increased approximately 19% from fiscal year
2005 to $17.2 million. In Cryo-Cell&#146;s most recently reported Q107, revenues increased by 13% over Q106, demonstrating that the Company has made continuing progress quarter over quarter; year over year. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In early 2006, the Cryo-Cell Board of Directors made the carefully evaluated decision to take a bold strategic step forward by investing in the growth of the business as
part of the Company&#146;s long-term strategic plan, with keen focus on repositioning the U-Cord&reg; service, expanding market reach and achieving product diversification. The Company continues to believe that this chosen strategy will serve as the
optimal pathway to create long-term and sustainable value for Cryo-Cell shareholders over time. Highlights of Cryo-Cell&#146;s progress include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The May 2007 announcement of Cryo-Cell&#146;s successful isolation of the maternal placental stem cell (MPSC) with new therapeutic potential for advancing
women&#146;s healthcare. Cryo-Cell has filed patent applications on its proprietary technology and is preparing to commercialize its technology into an exclusive new service offering involving the collection and preservation of maternal stem cells
from placenta at the time of birth. The Company is partnering with several prominent academic institutions specializing in regenerative medicine and has commenced preclinical (animal) studies as part of Cryo-Cell&#146;s MPSC commercialization
strategy. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The successful 2006 implementation of comprehensive strategic initiatives designed to reposition and re-brand Cryo-Cell&#146;s signature U-Cord&reg; product with
innovative industry-exclusive and competitively differentiated service enhancements. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company believes that Cryo-Cell is the only private family cord blood bank with the combination of current Good Manufacturing Practice/Good Tissue Practice
(cGMP/cGTP) compliance; International Organization for Standardization (ISO) and AABB (formerly American Association of Blood Banks) accreditation. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company delivered outstanding client satisfaction ratings for 2006 with nearly 40% of Cryo-Cell clients rating our service as &#147;far exceeds
expectations&#148; as measured in an independent survey conducted by Sterling Research Group, Inc.; <I>the highest such rating in the Company&#146;s history.</I> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Notwithstanding Cryo-Cell&#146;s significant progress since fiscal year 2003, rising industry costs in recent years associated with operating a state-of-the-art laboratory in a newly regulated environment, along with
increased expenses related to sales and marketing in an intensively competitive landscape, have contributed to the Company&#146;s predictable business challenge of balancing growth with profitability. The current Board and management team, however,
have remained steadfastly focused on building enterprise value rather than focusing attention on misguided efforts to affect the daily price of Cryo-Cell stock. The Cryo-Cell team believes that sustainable enterprise value creation will have the
most significant and positive impact on the Company&#146;s stock price over time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;As Cryo-Cell continues to execute the Company&#146;s long-term
strategy, the current Board and management team are guided along this journey by a collective vision of success based on the team&#146;s expansive business and technological knowledge, experience and industry-recognized expertise&#148;, stated
Mercedes Walton, Cryo-Cell&#146;s Chairman &amp; CEO. &#147;We are confident that the current board and management, with the addition of director nominee Andrew Filipowski, are best suited to build on the Company&#146;s success and to continue to
add value. Mr. Filipowski is one of the Company&#146;s single largest individual stockholders and brings a wealth of financial and strategic vision and experience and adds another independent-minded voice to the Board.&#148; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This year a group of dissident shareholders known as the Portnoy Group have launched a proxy contest in an effort to take control of Cryo-Cell. The Portnoy Group has a
conspicuous lack of relevant indicated professional experience in the stem cell preservation industry; regenerative science and women&#146;s healthcare; or relevant public company operating experience. The group consists of two brothers, David and
Mark Portnoy; an accountant with prior Portnoy affiliation; a professional with experience in water heaters and home comfort systems; a cardiologist; and a professional with experience in software and hardware integration solutions, also with prior
Portnoy affiliation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company believes that the Portnoy Group&#146;s overly simplistic platform to &#147;eliminate any and all unnecessary costs&#148;
and &#147;maximize the return from the deployment of CCII&#146;s marketing resources&#148; does not provide Cryo-Cell with any strategic direction or meaningful operating plan to create substantive shareholder value. The Company believes that Mr.
Portnoy&#146;s rhetoric will ring hollow in the new and complex frontier of regenerative medicine and women&#146;s healthcare that is governed by rigorous scientific, technological, regulatory and commercialization protocols. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;The Company has made significant operating progress along with several smart investments, and has most recently captured certain intellectual property surrounding
the Maternal Placental Stem Cells (MPSCs) which I believe are one of the most seminal assets in the stem cell industry today,&#148; said Andrew Filipowski, Director nominee to the Cryo-Cell Board. &#147;Given the Company&#146;s </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">ability to generate recurring revenue and strong cash flow from its core business, coupled with realizing value from its intellectual property in innovative
stem cell technology, the Company has the opportunity to be one of the global leaders in the space, and I believe the share price will follow. I am pleased to be nominated to the current Cryo-Cell Board of Directors and believe that the current
Board and management team have the vision, experience and proven performance to take the Company to global leadership in stem cell innovation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When
shareholders compare the track record, performance and qualifications of Cryo-Cell&#146;s current Board with the inexperienced Portnoy slate and their non-specific &#147;strategic&#148; plan, the Company believes that Cryo-Cell nominees are clearly
the right choice to progress a promising and robust long-term strategy. Shareholders are urged to cast their vote for the Cryo-Cell nominees by signing, dating and returning the white proxy card. Shareholders are also encouraged to discard the gold
proxy card of the dissident group. Any shareholders requiring assistance may contact Georgeson Inc. that is providing Cryo-Cell with proxy solicitation services at (888) 605-7511. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>About Cryo-Cell International, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Based in Oldsmar, Florida, with over 135,000 clients worldwide, Cryo-Cell is one
of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell
is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Forward-Looking Statement </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements wherein the terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148; or
&#147;expects&#148; as used are intended to reflect &#147;forward-looking statements&#148; of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ
materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential
service offerings relating to types of stem cells other than cord blood stem cells, given that such new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are subject to further research; the need
to complete certain developments, including completion of clinical validation and testing, before any such process can be commercialized, and the Company&#146;s development of its final business and economic model in offering any such service; any
adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem
cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs
relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company&#146;s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities;
any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters;
decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company&#146;s business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second
location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB
and any Current Reports on Form 8-K filed by the Company. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g73952img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73952img01.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````N#Z`1!1`0`!`````0#]`1%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`$2@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`#$`IP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/:/$7B&U\.Z?]HG^>1\B*$'!<_T
M'J:YFWL/%_B9!=7>IG2;5^8XH00V/H"#^9_"H8HQXG^)<YG&^STP$*AZ%E./
M_0LG\*]#J_A,U[WH<-)X*UNV'FV'BBZ,PZ+*6"GZG<?Y&G:+XMO[35QHGB6)
M8KDD".X``#D],XXY]1]*[>N<\6^%_P#A([>W\F9(+F!\K(PS\IZCCWP:%*^C
M&XVUB='17-S^(+C3O$>F:+<+$XFMO,FN"2,$!LGZ?+^M9T_C>]OKB6+P]H\M
M]%$=K7#9"D^P_P`32Y6/G1VM%<S8>)KA_%<FAW]M'"WE[X74GY^`<?EG\C73
M4FK#3N%%8'BGQ%)H,-HMO`MQ=74OEQQ,<9'<_F0/QJGJWC!K:^72M,LSJ&J8
MQ(L9^2,]\G_./6A1;$Y)'5T5QK:EXZ@3SI='T^5!RT43'>![?,?ZUJ:!XJL]
M<AE&UK:Z@!,T$O50.I'J*'%@I+8A\4>*TT$1VMO%]IU&?'E0C/&>`3CWZ#O6
M3%X=\5ZPHGU77I++=SY%OV'H=I`_G5;P3"=>\1:EXBNEW%7VP`\[2?\`!<#\
M:]#JF^71$I<VK.$E\)^)=-!GTKQ'//(.?*G)`;\R0?Q%:'A;Q:^J7,FEZG"+
M;5(<@KC`DQUP.Q]OQ%=77,:SX5EOO$MCK5G<)!+`5\T%3\X!]O49'TQ1>^X^
M6VL3IZ*QO$7B.S\.V:RW`,DTG$4*GYG/]![UBQZKXXO(Q<V^CV,,3#<D<['>
M1[_,/U`J5%C<DM#LZX^XU.]7XFVNG+<N+-H"S0_PD[6.?T%3Z)XO:ZU,Z1J]
MF;#41]U2<I)]/Z=<^M9US_R5^S_Z]C_Z`]4E:]Q.5TK%EM4OA\3DT[[2_P!C
M,.[R?X<["?YT54;_`)+`G_7O_P"TS12ET"/49X!X\1^(U?\`UGG?^SOG^E=_
M7G=T_P#PB?Q%-[-E=/U($,YZ*21G\F`/T->A@A@"""#R".]$][A#:PM%%<+\
M1M1\RUM=#MLO=W4JL8U_NYP!^+8_*DE=V*D[*Y2\:6;ZAX\TJS21H_/@$;,O
M4*6<-^F:]!M+6"QM8[:VB6.&-=JJHZ"N#N;,:?X_\,V:G(@LECSZX#C->A54
MMD3#=LXCQ];264NG>(K9?WMG*%DQW4G(S[9R/^!5V5M<1W=K#<PMNBE0.A]0
M1D5%J=C'J>F7-E+]R:,IGT/8_@>:XOPOKS:5X4U.VO.+G2"R[&[Y)VC_`+ZR
M/RI;H/AEZE75KUK_`,7ZCJ*_-;Z%;-Y>>AFYQ_X\3_WQ6M\.=.2'0FU-\O<W
MLC,SMUV@D8_,$_C571-#F;X=WQ8%KS48WG.1RW&5'XXS_P`"K0^'=]'=>%8K
M<-F6U=D<=QDEA^A_2JEMH3%>\FSK*Y+5?#T$_BD7L#O%/);E9`I`5P0RG/KQ
M_(5UM<9XIU25?%&D:99!&GF.)N.50L,'(]`&/]*X\5"K.FU1>OK;3KKT-X."
ME>>QI>$]/@TFTNK&#=@3&0ECGJ`./RKH:X;1M9N=*\87>BZJR+'-@VSA=H8]
MN?\`:'OU&*[FGAH584HJL[R"<H.3Y-@HHKSGQ?*/$7B[3="MB76!\SD=!G!;
M\E'ZXKH2N9RE9"27EC=_$VYGU6ZBBMK!`L`E<`;QCU]RQ_`5V/\`PE&@_P#0
M7L_^_HKC;;3=/D^)FIV.I6T<J7"F2$.."Q`;C\-WY5UO_"(>'_\`H%6_Y&KE
M;2Y$>;6QRWCW4-(OM/MKVPU"W?4+64&,Q2`MM/7\C@TL-S]M^)NDW6,>?8+)
MC_>C8_UK6UO3/"6@6:W-[I<6QW"*J)EB<$],^U9@2./XIZ8D,1BB6R`2,C!0
M>6V!^%-;":=]?(D;_DL"?]>__M,T4-_R6!/^O?\`]IFBHET+AU]3K-8T>TUS
M3WL[Q,J>58?>1O4&N3@T[QEX:'D:>\&J6*_<20X91^)!'T!(KO**2E8;BGJ<
M.^L>.;M?*M]#@MF/!E=AQ[C+8_G5WP[X0>POFU;5KG[9J;\ALY6/Z9ZGM[5U
M=%/F[!R]6<OJ>BWUSX[TO5(HU-I;Q;9'W`$'Y^W7N*ZBBBDW<:5@KS'Q9HOV
MGQY;V=M*5&I*C7"+V`/)/X+GZ@UV.O>)#H<T4?\`9MU=F52085R`<]#69X6L
M+Z^UF\\2:K;M;RS`1V\+YRB?0_0?KZU4;K4B5I>Z=='&D4:QQJ%1`%4#L!7&
MWOAK5-'U>75?#,D?[XYGLI#A6/7CM_+'8]JZ36?.^PQ^1OW_`&NVSLSG;YR;
MNG;&<^V:YO6&U:U?Q)=6_P!KEAD'D+"FXE"8%V21CV<D-CUS_#S*=BVDQS:Y
MXQF0PP^'(XICQYLDH*CWQD?SJUX;\+36%[+J^K7`NM5FZL/NQ@]A[]OIP*GU
MG28KO7]*E9+@JSN)C'-(JX",5R%('7%07D,<GBIWN#@#R?+W22CUSM"G:>?6
MGS=A<O5EWQ'X9L_$=JJRDQ7$?^JG49*^Q]1[5@0GQUHBB#R+?58%X60O\P'N
M203^.?K5S5K*]>\U&\ACE4Q3Q[)TN95=4"1EMD8&UOXNIP3G(-+XG_M.W?5[
MRR^TR1C3!&T$6XDD^=\\8'\:G;G')![D+0I=`<;NY2FO?'6K*8(-.ATU&X,S
M,-R_F2?R&:V?#'A2#P_&\SR&XOIO];.WYX'MG\Z9KO\`:LZVL.FQ2M);QBZ8
MB3RPSC[D;$]5;#[A[#UJ6^TVTU._TR]\NYVS'+XED3Y?+)7<H(QSC\:'+H"C
MK=D/BGPNVLM#?6,_V;4[;_5R=`PZ@$CIST/UJC'K7C*VC$%QX>CN)AQYT<H"
MM[D9_P`*U]1^W?9];^RF82^4ODE!E@=ISLSQN]/?%)I1M_[2/]FRW$EIY!\\
MRR2.!)D;<%R?FQOW=_NY[4<W1@XZW1C6OAW6-=U>'4O$QBCBMSF&RC.0#[X)
M&.G<YQ5R?1+Y_B);:NL2_8DA*,^\9SM8=.O<5%H(U2TN=&L;LW4L(M6E6>3<
M>"JYCD/]Y6SC/)!'4AC5G3)]2_MY[N>&<66H,Z1AF)$>P?NR%_A#*KL2>Y4>
ME',PY41-H=^?B*NL>4OV(1;=^\9SLQTZ]:*U-#O%DCGMI)'-PMU<DJX;(7SG
MV\GMC&/;%%)NXTK&O1112&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
..1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
